Sunday , May 16 2021

▷ Californian research team publishes promising results for a …



Santa Clara, Calif. (PRNewswire / -) – A team of researchers from Dr. Ing. The Rath Research Institute in California has developed a cancer vaccine that reduces tumor growth. This peptide-based vaccine specifically targets enzymes called metalloproteinases (MMPs), which are responsible for the development of tumors, the formation of metastases and blood vessels in tumors (angiogenesis). Dr. Rath's research team showed that the tested mice vaccinated with peptides containing specific MMP-2 and MMP-9 sequences and then infected with melanoma cancer cells had an average tumor volume of approximately 76% compared to non-vaccinated Animals from control team. It is noteworthy that some vaccinated animals did not show any cancer.

The study was published in October 2018 in the electronic journal Cellular Medicine and Physical Health.

Cancer is still the second largest epidemic worldwide. The disease causes more than 7 million deaths a year. This new treatment approach has the potential to drastically change these statistics. Compared with monoclonal antibodies (Mabs) or biologically similar molecules recently developed as anticancer agents, the MMP vaccine approach promises to be much more effective and accessible to the global fight against the disease. While Mabs / biosimilars target a particular type of cancer, the anti-MMP vaccine can fight all types of cancer. Another advantage is that, unlike Mabs / Biosimilars, where an injection is usually given once or twice a month, the anti-MMP vaccine should be injected only once and a vaccination after several years would be necessary .

The anti-MMP vaccine, if successfully completed, could be offered to patients from national or international healthcare facilities at a reasonable cost.

To make this valuable technology affordable for the majority of patients and nations around the world, the research institute, Dr. Rath has applied for patent protection in many countries. The institute seeks public and governmental research organizations and other nonprofit organizations to develop this promising technology with them, aiming at successful coping, prevention and ultimately eradication of cancer.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

U.S. Patent Nos. 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Communication:

Dr Alexandra Niedzwiecki
CEO
Dr. Rath Research Institute
Email: [email protected]


Source link